Volume 92, Issue 4 pp. 813-817
Valvular and Structural Heart Diseases

Maintenance of valvular integrity with Impella left heart support: Results from the multicenter PROTECT II randomized study

James A. Goldstein MD

Corresponding Author

James A. Goldstein MD

Beaumont Hospital Royal Oak, Royal Oak, Michigan

Correspondence James A. Goldstein, Beaumont Health System, 3601 W. 13 Mile Road, Royal Oak, Michigan 48073. Email: [email protected]Search for more papers by this author
Simon R. Dixon MBChB

Simon R. Dixon MBChB

Beaumont Hospital Royal Oak, Royal Oak, Michigan

Search for more papers by this author
Pamela S. Douglas MD

Pamela S. Douglas MD

Duke Clinical Research Institute, Durham, North Carolina

Search for more papers by this author
E. Magnus Ohman MD

E. Magnus Ohman MD

Duke University Medical Center, Durham, North Carolina

Search for more papers by this author
Jeffrey Moses MD

Jeffrey Moses MD

Columbia University Medical Center New York Presbyterian Hospital, New York

Search for more papers by this author
Jeffrey J. Popma MD

Jeffrey J. Popma MD

Beth Israel Deaconess Hospital, Boston, Massachusetts

Search for more papers by this author
William W. O'Neill MD

William W. O'Neill MD

Henry Ford Hospital, Detroit, Michigan

Search for more papers by this author
First published: 08 October 2017
Citations: 6

Abstract

Background

The Impella 2.5 axial flow pump, which is positioned across the aortic valve, is widely employed for hemodynamic support. The present study compared structural and functional integrity of the left heart valves in patients undergoing Impella vs intra-aortic balloon pump in the randomized PROTECT II trial.

Methods and Results

Transthoracic echocardiograms were performed at baseline, 1 and 3 months in 445 patients in the PROTECT II trial. Serial studies were analyzed by an independent echocardiography core laboratory for aortic and mitral valve structure and function, and left ventricular ejection fraction (LVEF). During Impella support there was no appreciable change in the degree of baseline valvular regurgitation. There were no cases of structural derangement of the mitral or aortic valve after use of the Impella device. At 90-day follow-up, there was an average 22% relative increase in LVEF from baseline (27% ± 9 vs. 33% ± 11, P < 0.001).

Conclusions

The present echocardiographic analysis of the PROTECT II study confirms prior observations regarding the safety of the Impella 2.5 device with respect to mitral and aortic valve function.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.